Yasin ŞAHİN, Özlem YILMAZ

How Should Helicobacter Pylori Eradication Be Performed in Cases of Extensive Allergies to Proton Pump Inhibitors?

In this presentation, we would like to discuss the path followed for drug selection in the case of a pediatric patient with extensive allergies to proton pump inhibitors (PPIs). A 15-year-old male patient presented with complaints of dyspepsia and epigastric pain for over a period of 4–5 years. It is known that there was a previous fixed drug eruption described with omeprazole and widespread rashes after lansoprazole. Famotidine treatment was initiated, but the patient was unable to use the drug because he presented with rash and itching 1 hour after drug intake. On physical examination, fixed drug eruption was observed in the whole body and gluteal region. Gastroduodenoscopy was performed. Macroscopically, the corpus and antrum were hyperemic, antrum and duodenum were nodular, and bulbus was normal. Multiple biopsies were taken. He was referred to the pediatric allergy department for evaluation of possible cross-reactivities between PPIs. In addition to skin prick and intradermal tests with famotidine and ranitidine, the patient underwent skin patch tests with all available PPIs. The pathologic result of biopsies was Helicobacter pylori (HP) (+++) with Giemsa staining. Because of the cross-sensitivity between PPIs and the positivity of the allergy tests, triple HP treatment was not considered. This is an interesting case because the patient had extensive allergies to all existing PPIs, and no similar cases have been reported yet in the literature. After evaluation of allergic tests, quadruple treatment without PPI (bismuth, ranitidine, metronidazole, and tetracycline) was initiated. HP treatment was assessed after 4 weeks, and two-step monoclonal stool HP antigen test was found to be negative.

PDF

___

Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life 2017; 10: 112-7.
Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014; 19(Suppl 1): 1-5.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212-39.
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017; 64: 991-1003.
van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19.
Malfertheiner P, Mégraud F, O’Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012; 5: 103-9.
Labenz J. Current role of acid suppressants in helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001; 15: 413-31.